Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.

Authors:
Stefania Cian, PharmD
Candice Garwood, PharmD, FCCP, BCPS, BCACP 

Reviewers:
Kristy Butler, PharmD, BSPharm, BCACP
Dave Dixon, PharmD, BCACP, CLS

Citation:
Dixon DL, Johnston K, Patterson J, et al. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States. JAMA Netw Open. 2023:6(11):e2341408-e2341408. doi: 10.1001/jamanetworkopen.2023.41408

The Problem

Currently, only 1 in 4 adults with hypertension have controlled blood pressure.¹ Hypertension and its complications come with high economic costs. Between 2003 and 2014, healthcare expenses associated with hypertension alone exceeded $130 billion in the United States (US).² Pharmacists are the most accessible health professionals and can play a vital role in screening and managing hypertension. Expanding pharmacist prescribing authority under collaborative practice agreements, standing orders, or statewide protocols may increase accessibility, especially for those with limited access to health services or who do not have a primary care provider. But would an expanded scope of practice that enabled pharmacists to prescribe and manage antihypertensive therapies be cost-effective?